argenx (Nasdaq:ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, visits the Nasdaq MarketSite in Times Square, in celebration of its initial public offering (IPO).
argenx (Nasdaq:ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, visits the Nasdaq MarketSite in Times Square, in celebration of its initial public offering (IPO).